Trial of 17-hydroxyprogesterone caproate (Proluton Depot) in women with long-standing infertility; failure of estrogen positive feedback the following cycle

References

• Soules M. R., Herbert Weibe R., Aksel S., Hammond C. B. The diagnosis and therapy of luteal phase deficiency. Fertil. Steril. 1977; 28: 1033
   PubMedGoogle Scholar
• Chez K. A. Proc. Symp. ‘Progesterone, progestins, and fetal development’. Fertil. Steril. 1978; 30: 16
   PubMed Web of Science ®Google Scholar
• De Moraes-Ruehsen M. D., Jones G. S., Burnett L. S., Baramki T. A. The aluteal cycle. Am. J. Obstet. Gynecol. 1969; 103: 1059
   Google Scholar
• Pearce M., Fahmy D., Morgan C., Evans C., Groom G., Boyns A. K., Cooke I. D. Hormonal changes in patients with defective luteal phases. J. Endocrinol. 1971; 51: xxiv
   Google Scholar
• Dodson K. S., Macnaughton M. C., Coutts J. R. T. Infertility in women with apparently ovulatory cycles. I. Comparison of their plasma sex steroid and gonadotrophin profiles with those in the normal cycle. Br. J. Obstet. Gynaecol. 1975; 82: 615
   PubMedGoogle Scholar
• Lenton E. A., Adams M., Cooke I. D. Plasma steroid and gonadotrophin profiles in ovulatory but infertile women. Clin. Endocrinol. 1978; 8: 241
   Google Scholar
• Wentz C. A., Herbert M. C., Maxson W. S., Garner C. H. Outcome of progesterone treatment of luteal phase inadequacy. Fertil. Steril. 1984; 41: 856
   PubMed Web of Science ®Google Scholar
• Abraham G. E., Maroulis G. B., Marshall J. R. Evaluation of ovulation and corpus luteum function using measurements of plasma progesterone. Obstet. Gynecol. 1974; 44: 522
   PubMed Web of Science ®Google Scholar
• Jones G. E. S. Luteal phase defects. Progress in Infertility, S. J. Behrman, K. W. Kistner. Little, Brown and Co., Boston 1975; 299
   Google Scholar
• Tyler E. T. The use of a new long-acting progestational compound (17-alpha-hydroxyprogesterone caproate) in infertility and habitual abortion. Stud. Fertil. 1957; 8: 85
   Google Scholar
• Maynard P. V., Baker P. N., Symonds E. M., Sant-Cassia L. H., Johnson J., Selby C. Nuclear progesterone uptake by endometrial tissue in cases of subfertility. Lancet 1983; 6: 310
   Google Scholar
• Browne J. S. L., Henry S., Venning E. H. The significance of endocrine assays in threatened and habitual abortion. Am. J. Obstet. Gynecol. 1939; 38: 927
   Google Scholar
• Javert C. T. Repeated abortion: results of treatment in 100 patients. Obstet. Gynecol. 1954; 3: 420
   PubMed Web of Science ®Google Scholar
• Junkmann K. Über protahiert wirksame Corticoide. Arch. Exp. Pathol. Pharmakol. 1954; 223: 280
   Google Scholar
• Rosenberg S. M., Luciano A. A., Riddick D. H. The luteal phase defect: The relative frequency of, and encouraging response to, treatment with vaginal progesterone. Fertil. Steril. 1980; 34: 17
   PubMed Web of Science ®Google Scholar
• Meyerhoff K. H., Brown W. H., Cioffi L. A. The use of 17-alpha-hydroxyprogesterone caproate to maintain pregnancy. Curr. Ther. Res. 1962; 4: 499
   Google Scholar
• Shearman R. P., Garrett W. J. Double-blind study of effect of 17-hydroxyprogesterone caproate on abortion rate. Br. Med. J. 1963; 5326: 292
   Google Scholar
• Levine L. Habitual abortion. A controlled study of progestational therapy. West. J. Surg. Obstet. Gynecol. 1964; 1: 30
   Google Scholar
• Johnson J. W. C., Austin K. L., Jones G. S., Davis G. H., King T. M. Efficacy of 17α-hydroxyprogesterone caproate in the prevention of premature labor. N. Engl. J. Med. 1975; 293: 675
   PubMed Web of Science ®Google Scholar
• Johnson J. W. C., Lee P. A., Zachary A. S., Calhoun S., Migeon C. J. High-risk prematurity—Progestin treatment and steroid studies. Obstet. Gynecol. 1979; 54: 412
   PubMedGoogle Scholar
• Varma T. R., Morsman J. Evaluation of the use of Proluton-Depot (hydroxyprogesterone hexanoate) in early pregnancy. Int. J. Gynaecol. Obstet. 1982; 20: 13
   Google Scholar
• Petsos P., Chandler C., Oak M., Ratcliffe W. A., Wood R., Anderson D. C. The assessment of ovulation by a combination of ultrasound and detailed serial hormone profiles in 35 women with long-standing unexplained infertility. Clin. Endocrinol. 1985; 22: 739
   PubMed Web of Science ®Google Scholar
• Ahmed A. G., Klopper A. Diagnosis of early pregnancy by assay of placental proteins. Br. J. Obstet. Gynaecol. 1983; 90: 604
   Google Scholar
• Heinonen O. P., Slone D., Monson R. R., Hook E. B., Shapiro S. Cardiovascular birth defects and antenatal exposure to female sex hormones. N. Engl. J. Med. 1977; 296: 67
   PubMed Web of Science ®Google Scholar
• Ortiz A., Hiroi M., Stanczyk F. Z., Goebelsmann U., Mishell D. R. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depot-MPA. J. Clin. Endocrinol. Metab. 1977; 44: 32
   PubMed Web of Science ®Google Scholar
• Larsson-Cohn U., Johansson E. D. B., Wide L., Gemzell C. Effects of continuous daily administration of 0.5 mg of chlormadinone acetate on the plasma levels of progesterone and on the urinary excretion of luteinizing hormone and total oestrogens. Acta Endocrinol. 1970; 63: 705
   PubMedGoogle Scholar
• Moghissi K. S., Marks C. Effects of microadose norgestrel on endogenous gonadotrophic and steroid hormones' cervical mucus properties, vaginal cytology and endometrium. Fertil. Steril. 1971; 22: 424
   PubMed Web of Science ®Google Scholar
• Elstein M., Bristol P. G., Hewitt K. J., Kirk D., Miller H. The effect of daily norethisterone (0.35 mg) on cervical mucus and on urinary LH, pregnanediol and oestrogen levels. Br J. Obstet. Gynaecol. 1976; 83: 165
   Google Scholar
• Nuttall I. D., Elstein M., Fahmy D. R. The effect of norethisterone capsules on the pituitary ovarian axis. Contraception 1982; 25: 51
   Google Scholar